Honored to receive the Appleseed teaching award— many of my favorite residents as a Duke med student were prior award recipients. One of the highlights of my intern year has been getting to engage with incredible Duke University School of Medicine medical students!

Incredible paper from Ziad Obermeyer et al. that provides further support to argument made by Utibe R. Essien, MD MPH Stacie Dusetzina and I in JAMA Health Forum jamanetwork.com/journals/jama-…. Cost-sharing for chronic disease treatments is likely killing patients and undermining health equity: reform needed!

If you are at #EPILifestyle24 make sure to catch Michael D. Green’s talk. His leadership on this important work has been incredible and the talk/poster will be well worth the visit!

Big news! Will be starting Preventive Medicine residency UNC Preventive Medicine Residency in July. I will deeply miss Duke Neurology, but am very excited to gain clinical, academic, and leadership training in public health in pursuit of a career as a clinician-leader in health systems transformation

Exciting news - Wegovy got a separate indication for MACE reduction in persons with CVD & overweight/obesity. Hopefully this new indication will improve coverage by those payers who have carve-outs for 'weight loss meds'- this it a CV prevention agent! fda.gov/news-events/pr…

The FLOW trial “achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression, MACE and death of 24% for people treated with semaglutide 1.0 mg compared to placebo”

novonordisk.com/news-and-media…

PSCK9 inhibitors reduced early recurrent stroke in patients with symptomatic intracranial atherosclerotic stenosis | Journal of Neurology, Neurosurgery & Psychiatry jnnp.bmj.com/content/early/…

This is the same guy from the VBG thing right? Dimethyl Fumarate as single best MS DMT is a pretty indefensible take when both natalizumab and ocrelizumab exist. There are even studies comparing showing ocrelizumab superior: jamanetwork.com/journals/jaman…

So honored to receive the third place prize in the AHA Science Lp(a) data challenge! Thanks to all the amazing mentors who supported me, especially Nishant Shah, MD! Looking forward to continuing to advance cardiovascular disease prevention.

Excited to share the Stanford Estimator of Electrocardiogram Risk (SEER), an AI risk score based on the ECG, out today in npj Digital Medicine with Marco Perez James Zou euan ashley David Ouyang, MD Pierre Elias, MD and many others! StanfordDBDS Cedars-Sinai Academic Medicine Columbia Cardiology Fellows 1/n

Absolutely fascinating JAMA paper this week suggesting that Cerebral Amyloid Angiopathy may actually be infectious. (Thread)

Excited to share our new study in JAMA Cardiology❗

⚠️ In the largest meta-analysis to date of 23 clinical trials (n=7407), regression of atherosclerotic plaque by 1% was associated with a 25% ⬇️ in MACE odds. Change in % atheroma volume could be a surrogate marker for MACE🫀

New NEJM
A GLP-1 drug (semaglutide) led to lack of need for insulin in 7 of 10 people with recent onset Type 1 (autoimmune) diabetes, and the other 3 of 10 had eliminated need for insulin w/ meals
nejm.org/doi/full/10.10…

Co-administered semaglutide and cagrilintide are safe and effective as a weight-loss treatment for patients with type 2 diabetes, study finds.
hubs.li/Q020W5r40

Oral semaglutide at 50 mg once per day led to a meaningful decrease in bodyweight compared with placebo in overweight adults without type 2 diabetes, study finds.
hubs.li/Q020V7DJ0

Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure | Circulation ahajournals.org/doi/abs/10.116…

🔥 BREAKING 🔥

Mikhail Kosiborod from Saint Luke's Mid America Heart Institute

❇️STEP-HFpEF, semaglutide
Obesity-phenotype HFpEF

🔆 Dual primary endpt. achieved

1. 🔼 health status (KCCQ)
2. 🔽 weight
3. 🚶 🔼 walk distance
4. Reduced NTproBNP

The beginning of a new era of therapies for this

Do we think that the rampant obesity stigma in medicine and policy will lead to difficulty implementing this secondary prevention strategy? I hope not but have been deeply disappointed by the resistance to using GLPs thus far.

SELECT trial: Among 17k w overweight/obesity (BMI >27) & CVD but w/o diabetes, semaglutide 2.4mg sc v placebo led to 20% reduction in MACE novonordisk.com/news-and-media… Novo Nordisk

I think these SELECT top line results are the most important for preventive cardiology since the JUPITER trial. Incredible implications for our field. ml-eu.globenewswire.com/Resource/Downl…